A genetic history captures details about the health of multiple generations.
This information can be important in diagnosing an inherited condition, revealing a pattern of inheritance, and informing clinical decisions regarding testing and management.
The key to navigating the social media landscape successfully is knowing how to leverage the positives and stay vigilant about the negatives.
Online harassment, misinformation, and divisive behavior have become all too common. This harmful behavior can negatively impact both advocates and the causes we strive to support.
As advocates, we set the tone for the communities we work with. We can inspire and uplift others by cultivating an environment of respect, empathy, and support. Especially in a world that sometimes feels divided and polarized, cultivating kindness and understanding becomes even more important. Let’s work together to make the online world a better place, where compassion and understanding prevail, and where our collective efforts lead to meaningful change.
A biomarker (also called a biological marker) is a piece of information about your health. Biomarkers include your blood pressure, your blood type, and cholesterol or blood sugar levels measured in a blood test. The biomarkers of cancer are also known as tumor markers. Biomarkers can tell your medical team important information about you and your cancer.
Colorectal cancer biomarkers can provide your medical team vital information about you and your cancer that is used to determine prognosis, guide treatment decisions, monitor treatment response, and look for recurrence after treatment. Biomarkers are also used in drug development to create and test targeted therapies for colorectal cancer.
The biomarkers that can confirm hereditary colorectal cancer are the DNA mismatch repair genes causing Lynch Syndrome, and the genes causing Familial Adenomatous Polyposis (FAP) and associated syndromes. Lynch Syndrome is caused by mutations in MLH1, MSH2, MSH3, MSH6, EPCAM, or PMS2 genes, while FAP and other polyposis syndromes are caused by mutations in APC, MYH, BMPR1A, and SMAD4.
The UK National Institute for Health and Care Excellence recommends universal testing for Lynch syndrome (LS) in all newly diagnosed colorectal cancer (CRC) patients. However, implementation varies significantly by geography. This project was developed to measure variation and deliver an effective diagnostic pathway from diagnosis of CRC to diagnosis of LS (within the RM Partners (RMP) West London cancer alliance).
The LS project was completed by April 2022. We have implemented a systematic approach with workforce transformation to facilitate identification and ‘mainstreamed’ genetic diagnosis of LS. This work has contributed to the development of a National LS Transformation Project in England which recommends local leadership within cancer teams to ensure delivery of diagnosis of LS and integration of genomics into clinical practice.
Health Innovation Hub Ireland (HIHI) was established by the Department of Business, Enterprise and Innovation and the Department of Health and is supported by Enterprise Ireland (EI) and the Health Service Executive (HSE) to drive collaboration between the health service and enterprise.
We offer companies the opportunity for pilot and clinical evaluation studies, and we provide the health service access to innovative products, services, and devices that they may not otherwise be exposed to.
HIHI is built on the recognition that collaboration with enterprise can benefit patient care, patient pathways and outcomes.
Experts say that millions of people are walking around with a genetic variant that raises their risk of developing cancer. The vast majority of them have no clue.
That’s a problem, because people who know they’re at a higher risk for certain cancers can take action, like going for more frequent screening tests such as colonoscopies and mammograms or even having preventive surgeries.
Asked why so few people get tested, both researchers and patients say that “many cancer doctors aren’t familiar with the latest research on inherited risk or that they don’t know the cost of testing has dropped”
The two best defined syndromes are Lynch syndrome (LS) and familial adenomatous polyposis (FAP). Studying these groups on regular cancer surveillance provides insight into the tumor biology, potential avenues for prevention, and their effectiveness. In this article, we will review some of the lessons that can be learned from these conditions which may afford opportunities for cancer prevention.
Hereditary syndromes provide an opportunity to study early precancer evolution surveillance and interventions to prevent cancer. Understanding genotype and phenotype in colorectal cancer susceptibility syndromes allows for customized clinical trials in preventive medicine to be highly effective in their outcomes.
The increasing knowledge of precancer lesions and their biology may aid novel strategies for individualized prevention. It is essential to consider the adverse effects of such interventions when weighed against quality of life, particularly considering the age at which medication may begin.
Exciting advancements are being made in the field of cancer vaccination against LS colorectal cancer, however until trials show their validity the recommended surveillance protocols must be upheld. Extrapolating information from these hereditary colorectal cancer studies can also help pinpoint how certain sporadic cancers evolve and offer opportunities for cancer prevention.
The training involves watching a short video which covers:
“Living with a hereditary cancer syndrome inevitably brings uncertainty. Despite taking preventative measures, the knowledge of increased risk frequently lingers in my mind.“
https://www.curetoday.com/view/the-upsides-and-downsides-of-cancer-genetic-testing
Taking a supplement of 30 grams of “resistant starch” a day – about the amount in two slightly unripe bananas – reduced the risk of multiple forms of cancer in people with a rare genetic condition.
Consuming resistant starch – a dietary fibre found in oatmeal, beans and bananas – reduces the risk of upper gastrointestinal cancers by nearly 50 per cent in people with Lynch syndrome. This is the first time a nutrient has been shown to prevent these cancers in people with the condition.
The nutrient supplement finding is significant because upper gastrointestinal cancers tend to be the deadliest for people with Lynch syndrome, says Matthew Yurgelun at the Dana-Farber Cancer Institute in Boston, Massachusetts, who wasn’t involved in the work.
See: Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up. https://www.capp3.org/media/26287/capr-22-0044_published_paper.pdf
Lynch Syndrome Ireland 